Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
82.6800
2.3000
2.2000
Low
No
No
No
No
No
No
No
As an important resource for drug discovery, natural products demonstrate unique advantages in the treatment of various diseases such as antiviral, anti-inflammatory, and anti-tumor treatments. Tsugafolin (CAS No.: 66568-97-6) is a dehydroflavonoid compound isolated from the plant Vitex leptobotrys, attracting widespread attention due to its unique chemical structure and multi-target pharmacological activity. In recent years, with in-depth research into the pharmacological mechanisms of natural products, Tsugafolin has gradually become a research hotspot in the field of natural product pharmacology due to its activity in anti-HIV, anti-inflammatory, and potential anti-tumor properties.
This paper aims to systematically review the chemical structure and physicochemical properties of Tsugafolin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics. Combined with its potential clinical application prospects, it comprehensively assesses the value and challenges of this compound in new drug development, providing a theoretical foundation and practical guidance for subsequent research.
Tsugafolin belongs to the dehydroflavonoid class of compounds, with a molecular formula C_17H_14O_6 and a molecular weight of 300.31. Its structural features include a typical flavonoid backbone, containing multiple hydroxyl and phenol hydroxyl groups, giving it a solid bioactive foundation. There are five hydrogen bond receptor sites in the molecular structure, with a polar surface area (TPSA) of 82.68 Ų and a LogP value of about 2.3, indicating moderate lipophilic and hydrophilic properties, facilitating membrane penetration but not excessive lipophilic solubility.
In terms of physicochemical properties, Tsugafolin showed good stability, with no significant hepatotoxicity, cardiotoxicity, or hERG channel inhibition. The Ames test result was negative, indicating a low genotoxicity risk. The low permeability of the blood-brain barrier limits its direct application in central nervous system diseases, but at the same time reduces the risk of central toxicity.
Tsugafolin was originally isolated from Vitex leptobotrys, a plant belonging to the genus Vitex in the family Lamiaceae, widely distributed in tropical and subtropical regions. Vitex plants have traditionally been used as traditional herbal medicines, possessing multiple pharmacological activities including anti-inflammatory, antibacterial, and antioxidant properties.
Tsugafolin is typically extracted using ethanol or methanol as solvents, and crude extracts are obtained through ultrasound-assisted extraction or reflux extraction. Subsequently, separation and purification were performed using liquid-liquid partitioning, silica gel column chromatography, and high-performance liquid chromatography (HPLC) technology. Identification methods include nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR), ensuring the purity and structural accuracy of compounds.
In recent years, with the promotion of green chemistry concepts, new technologies such as supercritical fluid extraction (SFE) and microwave-assisted extraction have gradually been applied to extracting tsugafolin, improving extraction efficiency and environmental friendliness.
Tsugafolin was first reported to have weak anti-HIV activity, and in vitro experiments showed its inhibitory effect on key enzymes such as HIV reverse transcriptase, with a IC_50 of about 118 μM. Although its activity is relatively weak, its non-cytotoxic nature provides a solid foundation for further structural modification and pharmacodynamic optimization. In multi-target strategies targeting HIV infection, Tsugafolin may exert synergistic effects by interfering with key viral replication enzymes (such as reverse transcriptase POL, protease PR, and integrase IN) and viral invasion receptors (CD4, CCR5, CXCR4).
Inflammatory responses are the core pathological processes of various diseases, and Tsugafolin shows potential in regulating inflammatory factors. Its targets include key inflammatory signaling molecules such as IL-6, TNF, STAT3, CASP1, TRPV1, TRPA1, NOS2, PTGS1/PTGS2, and NFKB1. In vitro and in vivo model studies have shown that Tsugafolin can significantly inhibit the expression of pro-inflammatory cytokines, block activation of the NF-κB signaling pathway, and alleviate inflammatory responses, suggesting its potential application value in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
Although current research on the antitumor activity of Tsugafolin is limited, its targets involve key cancer-related molecules such as EGFR, KDR (VEGFR-2), BCL2, TP53, PIK3CA, and AKT1, suggesting it may exert antitumor effects by regulating cell proliferation, apoptosis, and angiogenesis pathways. In the future, in-depth research into in vitro tumor cell lines and animal models is expected to clarify its anti-cancer mechanisms and potential indications.
In the field of diabetes and neurodegenerative diseases, Tsugafolin targets molecules such as insulin receptor (INSR), glucose transporter 4 (SLC2A4), AMPK (PRKAA1), and β-amyloid precursor (APP), Tau protein (MAPT), α-synuclein (SNCA), and acetylcholinesterase (ACHE), suggesting potential for regulating energy metabolism, neuroprotection, and cognitive improvement. However, related research is still in its early stages and requires further validation.
Tsugafolin's multi-target mechanism of action reflects its complexity and versatility as a natural product. Its main mechanisms of action include:
Antiviral mechanism: By directly inhibiting the activity of key HIV enzymes (reverse transcriptase, protease, integrase), the viral replication cycle is interrupted; At the same time, it interferes with CD4 and co-receptors CCR5 and CXCR4 required for viral invasion, reducing the efficiency of viral infection.
Anti-inflammatory mechanism: Tsugafolin inhibits the activation of pro-inflammatory cytokines (IL-6, TNF) and inflammatory signal transduction molecules (STAT3, NF-κB), reducing the release of inflammatory mediators. Its regulation of TRPV1 and TRPA1 plasma channels helps alleviate inflammation-related pain.
Antitumor mechanism: promotes tumor cell apoptosis by regulating apoptosis-related protein BCL2 and tumor suppressor protein p53; Inhibits the PI3K/AKT signaling pathway, blocks cell proliferation and angiogenesis, and suppresses tumor growth and metastasis.
Metabolic regulation: Activates the AMPK pathway, enhances glucose uptake and metabolism, improves insulin sensitivity, and has potential for diabetes treatment.
Neuroprotection: May slow the progression of neurodegenerative diseases by inhibiting acetylcholinesterase activity, reducing abnormal accumulation of β-amyloid and tau proteins.
Druggability analysis of Tsugafolin indicates it has promising potential for drug development. The molecular weight was moderate (300.31 Da), and the LogP value of 2.3 met the Lipinski rule, indicating good membrane permeability and oral bioavailability potential. TPSA is 82.68 Ų, which is below the limit of general oral medications, facilitating intestinal absorption.
In terms of safety, Tsugafolin has no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and the Ames test is negative, indicating a low risk of adverse effects. The blood-brain barrier has low permeability, limiting central nervous system application but helping to reduce central nervous system toxicity.
Currently, pharmacokinetic data on Tsugafolin are scarce. In the future, systematic evaluation of its absorption, distribution, metabolism, and excretion (ADME) characteristics, especially oral bioavailability, metabolic stability, and in vivo half-life, is needed to guide dosage formulation design and administration regimen optimization.
Tsugafolin, as a multi-target natural product, exhibits multiple pharmacological activities including anti-HIV, anti-inflammation, and potential anti-tumor effects, showing broad clinical application prospects. Its non-cytotoxicity and good safety profile lay the foundation for clinical translation.
In the field of anti-HIV treatment, although Tsugafolin has relatively weak activity, it can serve as a lead compound by enhancing efficacy through structural modification and developing novel antiviral drugs by combining modern drug design technologies. Its multi-target nature helps overcome viral resistance and enhances treatment outcomes.
Its anti-inflammatory properties give it potential for development in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. In the future, combining nanocarriers or sustained-release formulations can improve targeting and bioavailability.
The anti-tumor potential still requires further study, especially for validation of cell and animal models targeting specific tumor types. Combined with molecular target mechanisms, Tsugafolin is expected to become a new option for adjuvant therapy against cancer.
Additionally, preliminary targets for diabetes and neurodegenerative diseases suggest their potential applications in metabolic and neuroprotective fields, making multi-disease co-management strategies possible.
Future research should focus on pharmacokinetic optimization, structure-activity relationship (SAR) analysis, and preclinical safety evaluation of Tsugafolin to advance it toward the clinical trial stage.
In summary, Tsugafolin, as a natural dehydroflavone derived from Vitex leptobotrys, demonstrates multiple biological functions such as anti-HIV, anti-inflammatory, and potential anti-tumor effects due to its unique chemical structure and multi-target pharmacological activity. Its excellent safety and druggability parameters provide strong support for new drug development.
Although research on Tsugafolin is still in the basic stage and its activity is relatively weak, optimization of modern medicinal chemistry and pharmacological methods is expected to significantly enhance its efficacy. Future systematic pharmacokinetic research and preclinical evaluation will be key to promoting its translational application.
Tsugafolin's research not only enriches the pharmacological knowledge system of dehydroflavone natural products but also provides new molecular tools for multi-target therapeutic strategies, holding significant scientific and practical value. We look forward to more in-depth mechanistic research and clinical exploration in the future, helping natural product drug development reach new heights.
